Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

@article{Hon2010DevelopmentOC,
  title={Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.},
  author={St{\'e}phanie H{\'e}on and Beow Yong Yeap and Gregory J Britt and Daniel Botelho Costa and Michael S. Rabin and David Michael Jackman and Bruce Evan Johnson},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 23},
  pages={5873-82}
}
PURPOSE Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and elicit responses in patients with brain metastases (BM) from non-small cell lung cancer (NSCLC). However, there are incomplete data about their impact on the development and control of CNS metastases. EXPERIMENTAL DESIGN Patients with stage IIIB/IV NSCLC with somatic EGFR mutations initially treated with gefitinib or erlotinib were identified. The cumulative risk of CNS progression was calculated using… CONTINUE READING
69 Citations
46 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 69 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Randomized phase III trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406

  • PA Janne, XF Wang, MA Socinski, J Crawford, M Capelletti, MJ Edelman
  • J Clin Oncol. 2010;28:(suppl; abstr 7503)
  • 2010

Nonparametric Estimation of Partial Transition Probabilities in Multiple Decrement Models

  • O Aalen
  • Semin Oncol
  • 2009

Similar Papers

Loading similar papers…